M
Miquel Taron
Researcher at Autonomous University of Barcelona
Publications - 160
Citations - 18018
Miquel Taron is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Lung cancer & Erlotinib. The author has an hindex of 51, co-authored 160 publications receiving 16818 citations. Previous affiliations of Miquel Taron include University of Zaragoza & University of Barcelona.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rafael Rosell,Teresa Moran,Cristina Queralt,Rut Porta,Felipe Cardenal,Carlos Camps,Margarita Majem,Guillermo Lopez-Vivanco,Dolores Isla,Mariano Provencio,A. Insa,Bartomeu Massuti,José Luis González-Larriba,Luis Paz-Ares,Isabel Bover,Rosario García-Campelo,Miguel Angel Moreno,Silvia Catot,Christian Rolfo,Noemi Reguart,Ramon Palmero,Jose Miguel Sanchez,Roman Bastus,Clara Mayo,Jordi Bertran-Alamillo,Miguel Angel Molina,Jose Javier Sanchez,Miquel Taron +27 more
TL;DR: Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment, and the association between the mutations and the outcome of erlotinib treatment is analyzed.
Journal ArticleDOI
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang,Zhenfeng Zhang,Jae Cheol Lee,Luping Lin,Victor Olivas,Valerie Au,Thomas LaFramboise,Mohamed Abdel-Rahman,Xiaoqi Wang,Alan D. Levine,Jin Kyung Rho,Yun Jung Choi,Chang-Min Choi,Sang We Kim,Se Jin Jang,Young Soo Park,Woo Sung Kim,Dae Ho Lee,Jung Shin Lee,Vincent A. Miller,Maria E. Arcila,Marc Ladanyi,Philicia Moonsamy,Charles L. Sawyers,Titus J. Boggon,Patrick C. Ma,Carlota Costa,Miquel Taron,Rafael Rosell,Balazs Halmos,Trever G. Bivona,Trever G. Bivona +31 more
TL;DR: Increased activation of AXL and evidence for epithelial-to-mesenchymal transition (EMT) in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR p.Thr790Met alteration or MET activation are reported.
Journal Article
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
Reginald V. Lord,Jan Brabender,David R. Gandara,Vicente Alberola,Carlos Camps,Manuel Domine,Felip Cardenal,Jose Miguel Sanchez,Paul H. Gumerlock,Miquel Taron,Jose Javier Sanchez,K. D. Danenberg,Peter V. Danenberg,Rafael Rosell +13 more
TL;DR: Everexpression of the excision repair cross-complementing 1 (ERCC1) gene is a predictive factor for survival after CDDP/Gem therapy in advanced NSCLC and the presence of weight loss were significant prognostic factors for survival in a Cox proportional hazards multivariable analysis.
Journal ArticleDOI
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
M. Cobo,Dolores Isla,Bartomeu Massuti,Ana Montes,Jose Miguel Sanchez,Mariano Provencio,Nuria Viñolas,Luis Paz-Ares,Guillermo Lopez-Vivanco,Miguel Angel Muñoz,Enriqueta Felip,Vicente Alberola,Carlos Camps,Manuel Domine,Jose Javier Sanchez,Maria Sanchez-Ronco,K. D. Danenberg,Miquel Taron,David R. Gandara,Rafael Rosell +19 more
TL;DR: Assessment of ERCC1 mRNA expression in patient tumor tissue is feasible in the clinical setting and predicts response to docetaxel and cisplatin, and a multibiomarker profile predictive of patient outcome is refined.